BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36323660)

  • 1. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.
    Zimmerli D; Brambillasca CS; Talens F; Bhin J; Linstra R; Romanens L; Bhattacharya A; Joosten SEP; Da Silva AM; Padrao N; Wellenstein MD; Kersten K; de Boo M; Roorda M; Henneman L; de Bruijn R; Annunziato S; van der Burg E; Drenth AP; Lutz C; Endres T; van de Ven M; Eilers M; Wessels L; de Visser KE; Zwart W; Fehrmann RSN; van Vugt MATM; Jonkers J
    Nat Commun; 2022 Nov; 13(1):6579. PubMed ID: 36323660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.
    Lee KM; Lin CC; Servetto A; Bae J; Kandagatla V; Ye D; Kim G; Sudhan DR; Mendiratta S; González Ericsson PI; Balko JM; Lee J; Barnes S; Malladi VS; Tabrizi S; Reddy SM; Yum S; Chang CW; Hutchinson KE; Yost SE; Yuan Y; Chen ZJ; Fu YX; Hanker AB; Arteaga CL
    Cancer Immunol Res; 2022 Jul; 10(7):829-843. PubMed ID: 35561311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
    Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV; Housley F; Yau C; Nakagawa R; Winkler J; Anttila JM; Munne PM; Savelius M; Houlahan KE; Van de Mark D; Hemmati G; Hernandez GA; Zhang Y; Samson S; Baas C; Kok M; Esserman LJ; van 't Veer LJ; Rugo HS; Curtis C; Klefström J; Matloubian M; Goga A
    Nat Commun; 2022 Jun; 13(1):3671. PubMed ID: 35760778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibitor Efficacy Depends on CD8
    Pantelidou C; Sonzogni O; De Oliveria Taveira M; Mehta AK; Kothari A; Wang D; Visal T; Li MK; Pinto J; Castrillon JA; Cheney EM; Bouwman P; Jonkers J; Rottenberg S; Guerriero JL; Wulf GM; Shapiro GI
    Cancer Discov; 2019 Jun; 9(6):722-737. PubMed ID: 31015319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.
    Sceneay J; Goreczny GJ; Wilson K; Morrow S; DeCristo MJ; Ubellacker JM; Qin Y; Laszewski T; Stover DG; Barrera V; Hutchinson JN; Freedman RA; Mittendorf EA; McAllister SS
    Cancer Discov; 2019 Sep; 9(9):1208-1227. PubMed ID: 31217296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
    Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
    Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
    [No Abstract]   [Full Text] [Related]  

  • 11. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
    Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
    Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
    Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
    Hu MH; Wu TY; Huang Q; Jin G
    Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer.
    Jian Y; Huang X; Fang L; Wang M; Liu Q; Xu H; Kong L; Chen X; Ouyang Y; Wang X; Wei W; Song L
    J Exp Clin Cancer Res; 2021 Feb; 40(1):56. PubMed ID: 33541412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.